IGM Biosciencesの空売り状況は、投資家がIGM Biosciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

IGM Biosciences (NASDAQ:IGMS) 株価情報, 空売り情報

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Inc

Barclays analyst Adrienne Yih maintains Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) with a Equal-Weight and lowers the price target from $7 to $5.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Hanesbrands, Lowers Price Target to $5

Offerings

Old Republic Announces Prospectus Supplement Related To Offer By Sales Of Up To 2,829,509 Shares By At $1.00/Share

Barclays analyst Paul Kearney maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Underweight and lowers the price target from $25 to $21.

GIII

Barclays Maintains Underweight on G-III Apparel Group, Lowers Price Target to $21

Morgan Stanley analyst Vincent Andrews maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and lowers the price target from $125 to $115.

Morgan Stanley Maintains Overweight on Eastman Chemical, Lowers Price Target to $115

Citizens Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZWI#NASDAQ">CZWI</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.27 by 18.52 percent. This is a 17.95 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $14.19 million which beat the analyst consensus estimate of $11.60 million by 22.30 percent. This is a 6.47 percent decrease over sales of $15.17 million the same period last year.

Earnings

Earnings Beats

CZWI

Citizens Community Q1 Adj. EPS $0.32 Beats $0.27 Estimate, Sales $14.19M Beat $11.60M Estimate

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/HON/earnings">opening bell on Tuesday, April 29.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $2.21 per share, down from $2.25 per share in the year-ago period. Honeywell projects quarterly revenue of $9.6 billion, compared to $9.11 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 14, Citigroup analyst Andrew Kaplowitz maintained Honeywell with a Buy rating. He also lowered the price target from $253 to $229.
With the recent buzz around Honeywell, some investors may be eyeing potential gains from the company's dividends too. Currently, Honeywell offers an annual dividend yield of 2.27%. That&#8217;s a quarterly dividend of $1.13 per share ($4.52 a year).
To figure out how to earn $500 monthly from Honeywell, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Honeywell's $4.52 dividend: $6,000 / $4.52 = 1,327 shares.
So, an investor would need to own approximately $264,285 worth of Honeywell, or 1,327 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $4.52 = 265 shares, or $52,777 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
Price Action: Shares of Honeywell fell by 0.8% to close at $199.16 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Honeywell International Stock Ahead Of Q1 Earnings

Contracts

Hudbay Minerals Signs Agreement With The Mosakahiken Cree Nation On Exploration Activities In Their Traditional And Ancestral Territory, Including At Hudbay's Talbot Deposit South Of Snow Lake, Manitoba

As Big Tech steps onto the earnings stage this week, tariff worries swirl, but the AI Revolution isn't slowing down. Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) are all set to report and Wedbush Securities&#8217; analyst Dan Ives says the setup is more bullish than bearish.
<h2 class="wp-block-heading">Week Ahead: Big Tech&#8217;s Demand Trends In Focus</h2>
&#8220;This is a major week ahead for the markets and tech world,&#8221; Ives said as Wall Street braces for updates on cloud spending, digital ads, and enterprise AI budgets. Despite tariff noise dominating headlines, the Street is &#8220;laser-focused&#8221; on Big Tech demand trends &#8211; and Ives expects &#8220;generally very strong results&#8221; across the board.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44977897/exclusive-nvidia-alphabet-microsoft-amazon-meta-now-in-the-bargain-bin-after-being-heavily-sold-off-says-expert" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Nvidia, Alphabet, Microsoft, Amazon, Meta &#8211; Now In The Bargain Bin After Being &#8216;Heavily Sold Off&#8217;, Says Expert</a>
Microsoft and Amazon are riding a cloud spending surge, while Meta benefits from a digital advertising rebound. Even with the tariff overhang, Ives reports that CIOs and IT leaders have &#8220;very firm Cap-Ex intentions for 2025&#8221; in place, with AI deployments ramping across the enterprise landscape.
About 15% of IT budgets are now AI-driven — and those dollars are being fiercely defended.
<h2 class="wp-block-heading">Apple Could Take A 15-20% Hit</h2>
But for Apple, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44788262/apples-margins-catch-a-break-but-road-ahead-still-looks-bumpy">the tariff story looms large</a>. While the Cupertino-based company is expected to post solid results, the real question is what happens if the China tariffs stick.
Ives warns that in a worst-case scenario, Apple's 2025–26 numbers could take a 15–20% hit, although a quicker resolution could limit the damage to just 2–5%.
Still, Wedbush remains firmly in Apple&#8217;s corner, pointing to its &#8220;1.5 billion iPhone and 2.4 billion iOS installed base and massive Services business&#8221; as critical anchors for weathering the tariff storm.
Bottom line? Big Tech's earnings could serve as a significant &#8220;confidence booster&#8221; if investors can keep their eyes on the long-term AI prize and not get swept away by tariff turbulence.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44977897/exclusive-nvidia-alphabet-microsoft-amazon-meta-now-in-the-bargain-bin-after-being-heavily-sold-off-says-expert">S&amp;P 500, Magnificent 7 Hit Resistance: Analyst Warns Of More Pain Before Gain</a></li>
</ul>
Photo: Shutterstock

Previews

Tech

AAPL

AMZN

MSFT

Microsoft, Meta, Amazon, Apple Gear Up For 'AI Revolution' Week As Tariff Storm Brews

-&nbsp; Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working
-&nbsp; ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option
-&nbsp; ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs
NEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following treatment with Pluvicto. Pluvicto (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) directed radiotherapy radiolabeled with the beta-particle emitter, Lutetitium-177 (Lu-177) is approved for patients with metastatic castration-resistant prostate cancer. Pluvicto is marketed and sold by Novartis and generated sales of $1.39 billion in 2024.

ATNM

Actinium Pharma Announces ATNM-400 Preclinical Data Highlighting Sustained Tumor Control and Safety for Prostate Cancer Patients Post-Pluvicto

POET Technologies Inc. ("POET" or the "Corporation") (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/PTK#TSXV">PTK</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks today announces its intention to complete a non-brokered public offering of 5,000,000 units of the Corporation (the "Units") at a price of US$5.00 per Unit (the "Issue Price") for aggregate gross proceeds to the Corporation of US$25 million (the "Offering"). Each Unit will be comprised of one common share of the Corporation (each, a "Common Share") and one common share purchase warrant of the Corporation (each, a "Warrant"), with each Warrant being exercisable to acquire one Common Share at a price of C$8.32 for a period of five years from the date of issuance.
The Issue Price represents a premium of approximately 21.8% over the closing price of the Common Shares on the TSX Venture Exchange on Friday, April 25, 2025. The Corporation anticipates using the net proceeds of the Offering for working capital and general corporate purposes.

POET

TSXV:PTK

POET Technologies Announces $25M Offering Of 5M Units At A Price Of $5/Unit

CVLT

Commvault Wins GovRAMP Authorization Status For Commvault Cloud

CRWD

Commvault Expanded Partnership With CrowdStrike To Delver Unifed Set Of Services

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today is proud to announce a landmark achievement: our AmpliTech Inc. division has secured its highest value purchase order in history with the receipt this past Friday of a combined $2 million purchase orders for our proprietary Low Noise Amplifiers from a U.S. Fortune 500 company.
This major win for our core low noise amplifiers division marks the culmination of the most prolific four-month order period in our corporate history, driving our total backlog to nearly $20 million, all slated for delivery within Fiscal Year 2025.

AMPG

AmpliTech Group Division AmpliTech Inc. Receives Division Purchase Orders Of $2M From A Fortune 500 Company; Total Backlog To Nearly $20M, All Slated For Delivery Within Fiscal Year 2025

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Monday.
Shares of Eagle Financial Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) fell sharply in today's pre-market trading after the company released financial <a href="https://www.benzinga.com/quote/efsi">results for the first quarter</a>.
Eagle Financial Services reported quarterly earnings of 62 cents per share, down from 72 cents per share in the year-ago period.
Eagle Financial Services shares dipped 5.8% to $30.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) shares dipped 10.7% to $12.01 in pre-market trading. Truist Securities analyst Lucas Servera, on April 24, maintained RXO with a Buy and lowered the price target from $24 to $19.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) declined 9.8% to $12.01 in today's pre-market trading. ODP will announce first quarter financial results before the opening bell on Wednesday, May 7.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) shares fell 8.3% to $7.03 in pre-market trading.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) tumbled 6.8% to $6.81 in pre-market trading.</li>
<li>Magnera Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) dipped 6.8% to $13.41 in pre-market trading. Magnera is expected to report second quarter results on May 7.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) fell 6.4% to $9.13 in pre-market trading.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 2.8% to $13.35 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) slipped 2.2% to $11.85 in pre-market trading. Delcath Systems will host a conference call on May 8 to discuss results for its first quarter.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.5% to $109.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

ANNA

BLCO

DCTH

EFSI

HLMN

MAGN

NVDA

OMER

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada.
The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval.

Biotech

General

ACOG

Alpha Cognition To Present ZUNVEYL Clinical Data At 2025 AAIC

Elon Musk's space-based internet service provider, Starlink, could reportedly face delays in its plans to expand into India due to regulatory requirements.
What Happened: India's telecom minister, Jyotiraditya Scindia, reiterated that Musk's company must comply with stringent local regulations if it plans to operate in the country, <a href="https://www.rcrwireless.com/20250425/5g/starlink-india-telecom-minister">according</a> to RCR Wireless on Friday.
"The process is ongoing. The minute they meet all conditions — including setting up gateways in India and registering user terminals locally — we are ready to issue the license," Scindia said.
SpaceX did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
However, Starlink must go through a significant amount of red tape to get its license in India, as the process involves multiple government agencies like the Department of Telecommunications (DoT), the Telecom Regulatory Authority of India (TRAI), and the Indian National Space Promotion and Authorization Center (IN-SPACe).
"It's not only related to DoT, but also to internal security — gateways have to be in India, any user terminal has to be registered in India…the minute they check all the boxes, which I also hope will be soon, the license should be given," Scindia said, reiterating the importance of domestic gateways and user terminals.
Why It Matters: The news comes in as Starlink just added 13 more low-earth orbit satellites to its constellation aboard SpaceX's Falcon 9 rocket. Starlink has a healthy lead in the space-based internet race with its constellation boasting <a href="https://www.benzinga.com/general/space/25/04/44806935/spacex-launches-27th-falcon-9-rocket-from-florida-adds-27-starlink-satellites-to-orbit">over 7,000 satellites</a> and operating in more than 100 countries.
Starlink also recently<a href="https://www.benzinga.com/25/03/44268506/elon-musk-led-spacex-inks-agreements-with-indias-top-telecom-providers-expands-addressable-market-by-over-850-million-users"> signed an agreement</a> with two of India's major telecom providers, Bharati Airtel, as well as billionaire Mukesh Ambani's Jio Platforms Ltd., to provide satellite internet services in the country.&nbsp;
Musk has been eyeing India for a while, and spoke with Indian Prime Minister Narendra Modi recently, where the <a href="https://www.benzinga.com/general/space/25/04/44882314/tesla-ceo-elon-musk-indian-pm-modi-discuss-deeper-tech-ties-amid-model-y-test-run-in-mumbai">two reportedly discussed</a> ‘immense potential' for collaboration in ‘technology and innovation,' among other things.
On the other hand, Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper, Starlink's closest competitor, <a href="https://www.benzinga.com/general/space/25/04/44977151/jeff-bezos-space-internet-ambitions-falter-as-amazons-project-kuiper-struggles-to-increase-satellite-production-amid-launch-delays">faces significant challenges </a>in deploying its low Earth orbit satellites.
Elsewhere, SpaceX is among the ‘frontrunners' to build U.S. President Donald Trump's <a href="https://docs.google.com/document/d/1IAGucq2_2ZpFiUaXA_9zTDUHAjJYXHUzs3VLrbjGGKw/edit">Golden Dome Missile Defense System</a>, along with Peter Thiel's Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45029648/tesla-stock-skyrockets-20-following-elon-musks-return-and-shift-from-doge">Tesla Stock Skyrockets 20% Following Elon Musk&#8217;s Return and Shift From DOGE</a></li>
</ul>
Image Via Shutterstock

SPACE

PLTR

Elon Musk's India Ambitions Face Regulatory Hurdles Amid Uncertainty Around Starlink License: Report

ReShape Lifesciences&#xAE; (NASDAQ:<a href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, "Intragastric Device." When issued, the patent will cover claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion after deflation, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).

RSLS

Reshape Lifesciences Receives Notice Of Allowance From USPTO For Patent Application Entitled "Intragastric Device"

JP Morgan analyst Pablo Singzon maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Neutral and lowers the price target from $402 to $400.

KNSL

JP Morgan Maintains Neutral on Kinsale Cap Gr, Lowers Price Target to $400

Politics

OMEX

Odyssey Marine Exploration Confirms Sufficient Operational Funding And Welcomes New Executive Order By Trump Administration

WKHS

Workhorse Completes 2,400 Mile Drive In W56 Electric Step Van

Press Releases

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

Health Care

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

Comments

IGM Biosciences

空売り

IGM Biosciences (NASDAQ:IGMS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル